Drug induced stuttering: pharmacovigilance data

References

• Perez HR, Stoeckle JH. Stuttering: clinical and research update. Can Fam Physician. 2016;62(6):479–484.
   PubMedGoogle Scholar
• Metzger FL, Auer T, Helms G, et al. Shifted dynamic interactions between subcortical nuclei and inferior frontal gyri during response preparation in persistent developmental stuttering. Brain Struct Funct. 2018;223(1):165–182.
   PubMed Web of Science ®Google Scholar
• Mozos-Ansorena A, Pérez-García M, Portela-Traba B, et al. Stuttering treated with olanzapine: a case report. Actas Esp Psiquiatr. 2012;40(4):231–233.
   PubMed Web of Science ®Google Scholar
• Lasić D, Cvitanović MŽ, Krnić S, et al. Olanzapine induced stuttering: a case report. Psychiatr Danub. 2016;28(3):299–300.
   PubMed Web of Science ®Google Scholar
• Devroey D, Beerens G. Van de Vijver E. Methylphenidate as a treatment for stuttering: a case report. Eur Rev Med Pharmacol Sci. 2012;16(Suppl 4):66–69.
   PubMedGoogle Scholar
• Alpaslan AH, Coşkun KŞ, Kocak U, et al. Stuttering associated with the use of short-acting oral methylphenidate. J Clin Psychopharmacol. 2015;35(6):739–741.
   PubMed Web of Science ®Google Scholar
• Copur M, Copur S. Emergence of stuttering in an attention deficit hyperactivity disorder patient treated with methylphenidate. Dusunen Adam. 2018;31(2):222–224.
   Google Scholar
• Bate A, Lindquist M, Edwards IR. The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol. 2008;22(2):127–140.
   PubMed Web of Science ®Google Scholar
• Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol. 2004;57(2):127–134.
   PubMed Web of Science ®Google Scholar
• Faillie J-L. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74(2):225–232.
   PubMed Web of Science ®Google Scholar
• Yairi E, Ambrose N. Epidemiology of stuttering: 21st century advances. J Fluency Disord. 2013;38(2):66–87.
   PubMed Web of Science ®Google Scholar
• Theys C, van Wieringen A, Sunaert S, et al. A one year prospective study of neurogenic stuttering following stroke: incidence and co-occurring disorders. J Commun Disord. 2011;44(6):678–687.
   PubMed Web of Science ®Google Scholar
• Anderson JM, Hughes JD, Rothi LJ, et al. Developmental stuttering and Parkinson’s disease: the effects of levodopa treatment. J Neurol Neurosurg Psychiatry. 1999;66(6):776–778.
   PubMed Web of Science ®Google Scholar
• Giraud A-L, Neumann K, Bachoud-Levi A-C, et al. Severity of dysfluency correlates with basal ganglia activity in persistent developmental stuttering. Brain Lang. 2008;104(2):190–199.
   PubMed Web of Science ®Google Scholar
• Rabaeys H, Bijleveld H-A, Devroey D. Influence of methylphenidate on the frequency of stuttering: a randomized controlled trial. Ann Pharmacother. 2015;49(10):1096–1104.
   PubMed Web of Science ®Google Scholar
• Storebø OJ, Pedersen N, Ramstad E, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Cochrane Database Syst Rev. 2018;5:CD012069.
   PubMedGoogle Scholar
• Faraone SV. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255–270.
   PubMed Web of Science ®Google Scholar
• Wang G-J, Wiers CE, Shumay E, et al. Expectation effects on brain dopamine responses to methylphenidate in cocaine use disorder. Transl Psychiatry. 2019;9(1):93.
   PubMedGoogle Scholar
• Trenque T, Claustre G, Herlem E, et al. Methylphenidate and stuttering. Br J Clin Pharmacol. 2019;85(11):2634–2637.
   PubMed Web of Science ®Google Scholar
• Giray E, Şanal TC, Saçaklidir R, et al. Pregabalin-associated stuttering in a patient with complex regional pain syndrome: a case report. J Clin Psychopharmacol. 2016;36(6):740–742.
   PubMed Web of Science ®Google Scholar
• Mancano MA. ISMP adverse drug reactions. Hosp Pharm. 2017;52(4):253–257.
   PubMedGoogle Scholar
• Kuzniecky R, Ho S, Pan J, et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology. 2002;58(3):368–372.
   PubMed Web of Science ®Google Scholar
• Hoerbelt P, Lindsley TA, Fleck MW. Dopamine directly modulates GABAA receptors. J Neurosci. 2015;35(8):3525–3536.
   PubMed Web of Science ®Google Scholar
• Ertekin H, Ertekin YH, Sahin B, et al. Clozapine and aripiprazole-induced stuttering: a case report of Turner syndrome with schizophrenia. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology. 2016;26(4):329–444.
   Google Scholar
• Bär KJ, Häger F, Sauer H. Olanzapine- and clozapine-induced stuttering. A case series. Pharmacopsychiatry. 2004;37(3):131–134.
   PubMed Web of Science ®Google Scholar
• Chochol MD, Kataria L, O’Rourke MC, et al. Clozapine-associated myoclonus and stuttering secondary to smoking cessation and drug interaction: a case report. J Clin Psychopharmacol. 2019;39(3):275–277.
   PubMed Web of Science ®Google Scholar
• Murphy R, Gallagher A, Sharma K, et al. Clozapine-induced stuttering: an estimate of prevalence in the west of Ireland. Ther Adv Psychopharmacol. 2015;5(4):232–236.
   PubMed Web of Science ®Google Scholar
• Kumar T, Kathpal A, Longshore CT. Dose dependent stuttering with clozapine: a case report. Asian J Psychiatr. 2013;6(2):178–179.
   PubMedGoogle Scholar
• Duggal HS, Jagadheesan K, Nizamie SH. Clozapine-induced stuttering and seizures. Am J Psychiatry. 2002;159(2):315.
   PubMed Web of Science ®Google Scholar
• Rachamallu V, Haq A, Song MM, et al. Clozapine-induced microseizures, orofacial dyskinesia, and speech dysfluency in an adolescent with treatment resistant early onset schizophrenia on concurrent lithium therapy. Case Rep Psychiatry. 2017;2017:7359095.
   PubMedGoogle Scholar
• Krishnakanth M, Haridas Phutane V, Muralidharan K. Clozapine-induced stuttering: a case series. Prim Care Companion J Clin Psychiatry. 2008;10(4):333–334.
   PubMedGoogle Scholar
• Yadav DS. Risperidone induced stuttering. Gen Hosp Psychiatry. 2010;32(5):559.e9-10.
   PubMedGoogle Scholar
• Klein Hofmeijer-Sevink M, van Eijk ZJ. van der Zwaard R. Acquired stuttering in a psychotic patient. Tijdschr Psychiatr. 2009;51(1):53–57.
   PubMedGoogle Scholar
• Begum M. Clozapine-induced stuttering, facial tics and myoclonic seizures: a case report. Aust N Z J Psychiatry. 2005;39(3):202.
   PubMed Web of Science ®Google Scholar
• Nurnberg HG, Greenwald B. Stuttering: an unusual side effect of phenothiazines. Am J Psychiatry. 1981;138(3):386–387.
   PubMed Web of Science ®Google Scholar
• da Rocha FF. Aripiprazole-induced stuttering treated with risperidone. Braz J Psychiatry. 2009;31(4):388.
   PubMedGoogle Scholar
• Maguire GA, Riley GD, Franklin DL, et al. Risperidone for the treatment of stuttering. J Clin Psychopharmacol. 2000;20(4):479–482.
   PubMed Web of Science ®Google Scholar
• Lavid N, Franklin DL, Maguire GA. Management of child and adolescent stuttering with olanzapine: three case reports. Ann Clin Psychiatry. 1999;11(4):233–236.
   PubMedGoogle Scholar
• Lee HJ, Lee HS, Kim L, et al. A case of risperidone-induced stuttering. J Clin Psychopharmacol. 2001;21(1):115–116.
   PubMed Web of Science ®Google Scholar
• Tykalová T, Rusz J, Čmejla R, et al. Effect of dopaminergic medication on speech dysfluency in Parkinson’s disease: a longitudinal study. J Neural Transm (Vienna). 2015;122(8):1135–1142.
   PubMed Web of Science ®Google Scholar
• Prieto E, Micó JA, Meana JJ, et al. Neurobiological bases of quetiapine antidepressant effect in the bipolar disorder. Actas Esp Psiquiatr. 2010;38(1):22–32.
   PubMed Web of Science ®Google Scholar
• Jafari S, Fernandez-Enright F, Huang X-F. Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects. J Neurochem. 2012;120(3):371–384.
   PubMed Web of Science ®Google Scholar
• Guthrie S, Grunhaus L. Fluoxetine-induced stuttering. J Clin Psychiatry. 1990;51(2):85.
   PubMed Web of Science ®Google Scholar
• Christensen RC, Byerly MJ, McElroy RA. A case of sertraline-induced stuttering. J Clin Psychopharmacol. 1996;16(1):92–93.
   PubMed Web of Science ®Google Scholar
• McCall WV. Sertraline-induced stuttering. J Clin Psychiatry. 1994;55(7):316.
   PubMed Web of Science ®Google Scholar
• Brewerton TD, Markowitz JS, Keller SG, et al. Stuttering with sertraline. J Clin Psychiatry. 1996;57(2):90–91.
   PubMed Web of Science ®Google Scholar
• Brady JP. Drug-induced stuttering: a review of the literature. J Clin Psychopharmacol. 1998;18(1):50–54.
   PubMed Web of Science ®Google Scholar
• Ferris RM, White HL, Cooper BR, et al. Some neurochemical properties of a new antidepressant, bupropion hydrochloride (WellbutrinTM). Drug Dev Res. 1981;1(1):21–35.
   Web of Science ®Google Scholar
• Fetterolf F, Marceau M. A case of bupropion-induced stuttering. Gen Hosp Psychiatry. 2013;35(5):574.e7-8.
   PubMed Web of Science ®Google Scholar
• Bhatia MS. Bupropion-induced stuttering. Prim Care Companion CNS Disord. 2015;17(4). DOI:10.4088/PCC.15l01777
   Google Scholar
• Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–396.
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Sommet A, Bagheri H, et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905–908.
   PubMed Web of Science ®Google Scholar